Drug Profile
Research programme: radiolabeled imaging agents - Bioverativ/Invicro
Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Bioverativ; Invicro
- Class Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilia